Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 03/20/2026 | PUT | $7.50 | 107 | +2 | +1.90% |
| 03/20/2026 | CALL | $2.50 | 0 | 0 | |
| 03/20/2026 | CALL | $5.00 | 0 | 0 | |
| 03/20/2026 | CALL | $7.50 | 593 | 0 | |
| 03/20/2026 | CALL | $10.00 | 10 | 0 | |
| 03/20/2026 | CALL | $12.50 | 0 | 0 | |
| 08/21/2026 | PUT | $5.00 | 0 | 0 | |
| 08/21/2026 | PUT | $7.50 | 3 | 0 | |
| 08/21/2026 | PUT | $10.00 | 0 | 0 | |
| 08/21/2026 | PUT | $12.50 | 0 | 0 | |
| 08/21/2026 | PUT | $15.00 | 0 | 0 | |
| 08/21/2026 | PUT | $17.50 | 0 | 0 |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight
01/14 02:00 pm
GlobeNewswire Inc.
Read moreJohnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment
01/06 02:42 pm
Benzinga
Read moreAstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
07/24 01:08 pm
Benzinga
Read moreCartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
05/08 07:00 am
GlobeNewswire Inc.
Read moreUS Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert
04/09 05:53 am
Benzinga
Read moreCAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain
03/05 02:00 pm
GlobeNewswire Inc.
Read moreBy 2034, CAR-T Cell Therapy Market Set to Soar USD 8.7 Billion, at 1.80% CAGR: Prophecy Market Insights
08/27 08:49 am
GlobeNewswire Inc.
Read moreCartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research
07/03 02:30 pm
Zacks Investment Research
Read moreCartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus
07/02 06:31 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces $130 Million Private Placement Equity Financing
07/02 06:31 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis
07/02 06:30 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces New Employment Inducement Grant
06/06 07:05 am
GlobeNewswire Inc.
Read moreCartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08
05/23 12:12 pm
Zacks Investment Research
Read moreCartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis
05/22 07:00 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
05/13 04:30 pm
GlobeNewswire Inc.
Read moreWhat Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock
05/13 12:00 pm
Zacks Investment Research
Read moreWall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet
05/13 09:55 am
Zacks Investment Research
Read moreCartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
05/08 07:00 am
GlobeNewswire Inc.
Read moreWall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade
04/25 09:55 am
Zacks Investment Research
Read moreCartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
04/10 02:34 pm
Benzinga
Read moreDown -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
04/08 09:35 am
Zacks Investment Research
Read moreCartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
03/28 04:05 pm
GlobeNewswire Inc.
Read moreLivePerson And 2 Other Stocks Under $2 Insiders Are Buying
03/19 07:55 am
Benzinga
Read moreCartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
03/14 09:35 am
Zacks Investment Research
Read moreCartesian Therapeutics to Participate in Upcoming Investor Conferences
03/06 08:00 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces New Employment Inducement Grant
03/05 08:05 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
03/05 08:00 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces New Employment Inducement Grants
02/05 05:05 pm
GlobeNewswire Inc.
Read moreCartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
01/08 08:10 am
GlobeNewswire Inc.
Read moreCartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
01/08 08:00 am
GlobeNewswire Inc.
Read moreEmergent Biosolutions (EBS) Reports Q3 Loss, Tops Revenue Estimates
12/11 11:05 am
Zacks Investment Research
Read more